Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques
Launched by ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO · Nov 16, 2017
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
A retrospective, national, multicenter study
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Age between 18 to 43 years 'old at the time of the beginning of ulipristal acetate intake
- • 2. Women with fibroid at the time of ulipristal acetate prescription
- • 3. Women with desire to have children and managed for infertility in an ART center (whatever the type of infertility treatment)
- • 4. Women having received a treatment by ulipristal acetate
- • 5. Data collected between 2013/12/01 and 2018/06/30 ; data collected between ulipristal acetate prescription until the term of pregnancy or embryo transfer failure (up to 4) or death/lost to follow up or ART treatment discontinuation
- Exclusion Criteria:
- • none
About Association Pour Le Developpement En Fecondation In Vitro
The Association pour le Développement en Fécondation In Vitro (ADFIV) is a leading organization dedicated to advancing the field of assisted reproductive technologies, specifically in vitro fertilization (IVF). Committed to enhancing patient care and outcomes, ADFIV focuses on innovative research, clinical trials, and educational initiatives that promote best practices in reproductive health. Through collaboration with healthcare professionals, researchers, and patients, ADFIV strives to improve access to fertility treatments and contribute to the scientific community's understanding of reproductive medicine, ultimately fostering advancements that benefit individuals and families seeking to overcome infertility challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Angers, , France
Lille, , France
Toulouse, , France
Rennes, , France
Bruges, , France
Dijon, , France
Nice, , France
Bordeaux, , France
Besançon, , France
Nîmes, , France
Nîmes, , France
Créteil, , France
Ecully, , France
Marseille, , France
Marseille, , France
Montpellier, , France
Montpellier, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Schiltigheim, , France
Nouméa, , New Caledonia
Patients applied
Trial Officials
Catherine RONGIERES, MD
Principal Investigator
ADEFIV & University Hospitals of Strasbourg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials